Two pharmaceutical companies - Merck & Co Inc. and Pfizer Inc. - have just announced that they have partnered up for the development of the type 2 diabetes drug ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor. There's been a huge rise in the number of treatment options for people suffering from diabetes over the past years, with close to 25 million Americans diagnosed with diabetes, the condition costs the U.S. over $245 billion a year...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment